Elanco Animal Health Inc(ELAN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.4 | Insider Own | 1.02% | Shs Outstand | 499.6M | Perf Week | -7.37% |
| Market Cap | 11.42B | Forward P/E | 17.96 | EPS next Y | 12.25% | Insider Trans | 1.45% | Shs Float | 494.6M | Perf Month | 0.57% |
| Enterprise Value | 14.81B | PEG | 1.16 | EPS next Q | 0.21 | Inst Own | 113.83% | Short Float | 6.01% | Perf Quarter | -0.04% |
| Income | -0.20B | P/S | 2.28 | EPS this Y | 20.62% | Inst Trans | 4.21% | Short Ratio | 5 | Perf Half Y | -2.52% |
| Sales | 5.02B | P/B | 1.73 | EPS next 5Y | 15.54% | ROA | -1.46% | Short Interest | 29.72M | Perf YTD | 1.02% |
| Book/sh | 13.19 | P/C | 21.55 | EPS past 3/5Y | -43.04% 18.11% | ROE | -2.98% | 52W High | -18.3% ($27.98) | Perf Year | 24.71% |
| Cash/sh | 1.06 | P/FCF | 30.14 | Sales past 3/5Y | 2.25% 7.57% | ROIC | -1.91% | 52W Low | 25.47% ($18.22) | Perf 3Y | 97.24% |
| Dividend Est. | - | EV/EBITDA | 14.43 | EPS Y/Y TTM | -145.71% | Gross Margin | 44.28% | Volatility(W/M) | 3.41% 2.9% | Perf 5Y | -31.52% |
| Dividend TTM | - | EV/Sales | 2.95 | Sales Y/Y TTM | 11.95% | Oper. Margin | 6.63% | ATR (14) | 0.85 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.1 | EPS Q/Q | 380.63% | Profit Margin | -3.96% | RSI (14) | 39.38 | Recom | 1.28 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.05 | Sales Q/Q | 10.23% | SMA20 | -4.84% ($24.02) | Beta | 1.7 | Target Price | $31.46 |
| Payout | - | Debt/Eq | 0.59 | Earnings | 2026/8/5 | SMA50 | -6.94% ($24.56) | Rel Volume | 0.95 | Prev Close | $23.55 |
| Employees | 9900 | LT Debt/Eq | 0.58 | EPS/Sales Surpr. | 26.3% 4.23% | SMA200 | -3.82% ($23.77) | Avg Volume(3M) | 5.95M | Price | $22.86 |
| IPO | 2018/9/20 | Option/Short | Yes/Yes | Trades | 26414 | Volume | 5,633,944 | Change | -2.93% |
Company
ELAN is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
A US-based animal health company that develops and manufactures pharmaceuticals and vaccines for both companion animals and livestock, supplying veterinarians and livestock producers worldwide as a global animal healthcare leader. The company was spun off from Eli Lilly and operates as an independent publicly traded entity.
Over the past 1 year, roughly in the middle
18% below its 1-year high.
ELAN has weak earning power
6.63% of revenue is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +20.6% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by +97.2% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 113.8%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
ADPV 0.04%
IHE 0.03%
BSMC 0.03%
JHAC 0.02%
TMED 0.02%Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
EIRL 80M
GLCR 1M
TELG -It ranks #4 in the industry
Based on market cap of $11B.
ELAN $11B PER -
TAK $58B PER -
TEVA $42B PER 61.1
HLN $41B PER 19.0
FAQ
What kind of company is ELAN?
ELAN belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of ELAN?
The market cap of ELAN is approximately $11.4B, ranking 864 within its sector.
What is the 52-week high and low for ELAN?
ELAN has recorded a 52-week high of $27.98 and a low of $18.22.
